Top Industry Leaders in the Osteoporosis Drugs Market
Merck Acquires Acceleron Pharma for $11.5 Billion: January 2024 deal strengthens Merck's position in the bone health market with Acceleron's romosozumab (Evenity), a first-in-class bone-building drug for postmenopausal women with osteoporosis.
Amgen Partners with Eli Lilly for Development and Commercialization of New Bone Anabolic Agent: January 2024 collaboration combines expertise to accelerate the development and market access of Lilly's LY3022780, a promising bone anabolic drug in late-stage clinical trials.
Novartis Launches Prolia® Subcutaneous Injection in Europe: February 2024 launch offers a new, convenient administration option for this widely used bisphosphonate medication for osteoporosis treatment.
Bone Therapeutics Announces Positive Phase 2a Data for Bone Formation Stimulation Using BoneBOOST™ Peptide: December 2023 development showcases the potential of this novel therapy for stimulating bone formation and treating osteoporosis.
List of Osteoporosis Drugs Key Companies in the Market
- Teva Pharmaceutical Industries Ltd
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd
- Actavis plc